{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:14:34Z","timestamp":1768486474093,"version":"3.49.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejpb.2025.114924","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:31:01Z","timestamp":1763346661000},"page":"114924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Compatibility of parenteral nutrition solutions with intravenous medication in infants and children: A literature review"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9705-6083","authenticated-orcid":false,"given":"Mahmoud","family":"Farhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"McCallion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Cram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.clnme.2013.06.001","article-title":"Review of drug stability in parenteral nutrition admixtures","volume":"8","author":"Cardona","year":"2013","journal-title":"e-SPEN Journal"},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0010","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/0148607114521833","article-title":"A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing","volume":"38","author":"Boullata","year":"2014","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"10.1016\/j.ejpb.2025.114924_b0015","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/S0261-5614(16)30535-0","article-title":"SUN-P192: drugs compatibility with parenteral nutrition","volume":"35","author":"Acramel","year":"2016","journal-title":"Clin. Nutr."},{"issue":"7","key":"10.1016\/j.ejpb.2025.114924_b0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/pharmaceutics12070677","article-title":"Y-site physical compatibility of numeta G13E with drugs frequently used at neonatal intensive care","volume":"12","author":"Nezvalova-Henriksen","year":"2020","journal-title":"Pharmaceutics"},{"issue":"001","key":"10.1016\/j.ejpb.2025.114924_b0025","first-page":"2017","article-title":"Multiport Y-site compatibility studies of a parenteral nutrition solution with routinely used pediatric CVICU medications","volume":"1","author":"Gorman","year":"2017","journal-title":"Advan Crit. Care Med."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0030","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0148607112464239","article-title":"Compatibility of intravenous medications with parenteral nutrition: in vitro evaluation","volume":"37","author":"Bouchoud","year":"2013","journal-title":"Jpen J. Parenteral Enteral Nutr."},{"key":"10.1016\/j.ejpb.2025.114924_b0035","unstructured":"Pharmacopeia, U.S., Visible Particulates in Injections.\u201c United States Pharmacopeial Convention, (USP) 43\u2013NF 38. \u201dChapter <790>:. 2020."},{"key":"10.1016\/j.ejpb.2025.114924_b0040","unstructured":"Pharmacopeia, E. European Pharmacopeia Online. 2025; Available from: https:\/\/pheur-online.edqm.eu\/home\/."},{"key":"10.1016\/j.ejpb.2025.114924_b0045","unstructured":"Harmonisation, T.I.C.f. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). 2025; Available from: https:\/\/www.ich.org\/."},{"key":"10.1016\/j.ejpb.2025.114924_b0050","unstructured":"MIDLINE on OvidSP. Available from: https:\/\/www.wolterskluwer.com\/en\/solutions\/ovid\/ovid-medline-901."},{"key":"10.1016\/j.ejpb.2025.114924_b0055","unstructured":"CINAHL\u00ae Complete Available from: https:\/\/www.ebsco.com\/products\/research-databases\/cinahl-complete."},{"key":"10.1016\/j.ejpb.2025.114924_b0060","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejpb.2025.114924_b0065","unstructured":"Institute, J.B., the critical appraisal tool for Quasi-Experimental Studies (experimental studies without random allocation). 2017, Joanna Briggs Institute."},{"issue":"11","key":"10.1016\/j.ejpb.2025.114924_b0070","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/ajhp\/54.11.1295","article-title":"Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration","volume":"54","author":"Trissel","year":"1997","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/014860719902300267","article-title":"Compatibility of medications with 3-in-1 parenteral nutrition admixtures","volume":"23","author":"Trissel","year":"1999","journal-title":"Jpen J. Parenteral Enteral Nutr."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0080","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/0148607114521833","article-title":"A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing","volume":"38","author":"Boullata","year":"2014","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114924_b0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5863\/1551-6776-14.1.48","article-title":"Y-site compatibility of medications with parenteral nutrition","volume":"14","author":"Robinson","year":"2009","journal-title":"J. Pediatric Pharmacol. Therapeutics"},{"key":"10.1016\/j.ejpb.2025.114924_b0090","series-title":"Handbook on Injectable Drugs","year":"2009"},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0095","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0022-3476(88)83215-3","article-title":"Antibiotic stability in a pediatric parenteral alimentation solution","volume":"112","author":"Fox","year":"1988","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1699-0463.1988.tb05310.x","article-title":"Stability of ampicillin, piperacillin, cefotaxime, netilmicin and amikacin in an L-amino acid solution prepared for total parenteral nutrition of newborn infants","volume":"96","author":"Goldstein","year":"1988","journal-title":"APMIS"},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1128\/AAC.13.4.555","article-title":"Stability of antibiotics and amino acids in two synthetic L-amino acid solutions commonly used for total parenteral nutrition in children","volume":"13","author":"Colding","year":"1978","journal-title":"Antimicrobial Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114924_b0110","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1542\/peds.51.6.1016","article-title":"Antibiotic stability in solutions used for intravenous nutrition and fluid therapy","volume":"51","author":"Feigin","year":"1973","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0115","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/jphp.12647","article-title":"Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents","volume":"69","author":"Staven","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114924_b0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/ejhpharm-2018-001562","article-title":"Physical stability of an all-in-one parenteral nutrition admixture for preterm infants upon mixing with micronutrients and drugs","volume":"27","author":"Staven","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"issue":"21","key":"10.1016\/j.ejpb.2025.114924_b0125","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1093\/ajhp\/53.21.2611","article-title":"Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs","volume":"53","author":"Veltri","year":"1996","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0130","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/0148607185009002220","article-title":"Piggyback compatibility of antibiotics with pediatric parenteral nutrition solutions","volume":"9","author":"Watson","year":"1985","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00006454-198507000-00011","article-title":"Analysis of antibiotic stability in a parenteral nutrition solution","volume":"4","author":"Kamen","year":"1985","journal-title":"Pediatr. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0140","first-page":"313","article-title":"Compatibility of drugs with a heparin-containing neonatal total parenteral nutrient solution","volume":"45","author":"Schilling","year":"1988","journal-title":"Am. J. Hosp. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114924_b0145","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2146\/ajhp110715","article-title":"Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration","volume":"70","author":"Fox","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0150","doi-asserted-by":"crossref","first-page":"04","DOI":"10.3390\/ph12020067","article-title":"Investigations of physical compatibilities of commonly used intravenous medications with and without parenteral nutrition in pediatric cardiovascular intensive care unit patients","volume":"12","author":"Greenhill","year":"2019","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0155","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ajhp\/59.5.452","article-title":"Physical compatibility of milrinone lactate injection with intravenous drugs commonly used in the pediatric intensive care unit","volume":"59","author":"Veltri","year":"2002","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114924_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190577","article-title":"Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion","volume":"13","author":"Garcia","year":"2018","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"12","key":"10.1016\/j.ejpb.2025.114924_b0165","first-page":"2496","article-title":"Effect of retrograde aminophylline administration on calcium and phosphate solubility in neonatal total parenteral nutrient solutions","volume":"46","author":"Kirkpatrick","year":"1989","journal-title":"Am. J. Hosp. Pharm."},{"issue":"8587","key":"10.1016\/j.ejpb.2025.114924_b0170","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(88)91492-4","article-title":"Incompatibility between fat emulsion and calcium plus heparin in parenteral nutrition of premature babies","volume":"1","author":"Raupp","year":"1988","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/0148607198022005311","article-title":"Pharmacologic levels of heparin do not destabilize neonatal parenteral nutrition","volume":"22","author":"Silvers","year":"1998","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"12","key":"10.1016\/j.ejpb.2025.114924_b0180","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/ajhp\/58.12.1139","article-title":"Stability of methylprednisolone sodium succinate in pediatric parenteral nutrition mixtures","volume":"58","author":"Gellis","year":"2001","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/archdischild-2019-317912","article-title":"Compatibility of pentoxifylline and parenteral medications","volume":"105","author":"Campbell","year":"2020","journal-title":"Arch. Dis. Child."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0190","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0261-5614(99)80006-5","article-title":"Stability and compatibility of teicoplanin in parenteral nutrition solutions used in pediatrics","volume":"18","author":"Tounian","year":"1999","journal-title":"Clin. Nutr."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0195","first-page":"362","article-title":"Compatibility of total nutrient admixtures and secondary antibiotic infusions","volume":"42","author":"Baptista","year":"1985","journal-title":"Am. J. Hosp. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114924_b0200","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1590\/S1679-45082016AO3440","article-title":"Compatibility: drugs and parenteral nutrition","volume":"14","author":"Miranda","year":"2016","journal-title":"Einstein"},{"issue":"23","key":"10.1016\/j.ejpb.2025.114924_b0205","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/ajhp\/zxaa299","article-title":"Compatibility of medications with intravenous lipid emulsions: effects of simulated Y-site mixing","volume":"77","author":"Ross","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0210","doi-asserted-by":"crossref","first-page":"06","DOI":"10.3390\/nu11030559","article-title":"Effect of lipid emulsion on stability of ampicillin in total parenteral nutrition","volume":"11","author":"Stawny","year":"2019","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0215","first-page":"511","article-title":"Visual compatibility of 30 additives with a parenteral nutrient solution","volume":"36","author":"Athanikar","year":"1979","journal-title":"Am. J. Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0220","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000492940","article-title":"Compatibility of intravenous fat emulsion with antibiotics for secondary piggyback infusion","volume":"73","author":"Omotani","year":"2018","journal-title":"Ann. Nutr. Metab."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0225","first-page":"777","article-title":"Compatibility of total nutrient admixtures and secondary cardiovascular medications","volume":"42","author":"Baptista","year":"1985","journal-title":"Am. J. Hosp. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0230","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/0148607189013005505","article-title":"The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures","volume":"13","author":"Bullock","year":"1989","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114924_b0235","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000237861","article-title":"Antibiotic compatibility and stability in a parenteral nutrition solution","volume":"25","author":"Reed","year":"1979","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejpb.2025.114924_b0240","unstructured":"de Juana, P., et al., [The stability of antibiotics administered in and with a parenteral nutrition mixture enriched with branched-chain amino acids. I. Amikacin and gentamycin]. Nutricion Hospitalaria, 1993. 8(1): p. 30-7."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/014860719902300267","article-title":"Compatibility of medications with 3-in-1 parenteral nutrition admixtures","volume":"23","author":"Trissel","year":"1999","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0250","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/antibiotics10020217","article-title":"Toward safe pharmacotherapy: the interplay between meropenem and parenteral nutrition admixtures","volume":"10","author":"Gostynska","year":"2021","journal-title":"Antibiotics"},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0255","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0148607191015005536","article-title":"In vitro assessment of vancomycin HCl compatibility after coinfusion with a specialized amino acid formulation.","volume":"15","author":"Martins","year":"1991","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114924_b0260","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/014860718901300163","article-title":"Stability and delivery of vancomycin hydrochloride when admixed in a total parenteral nutrition solution","volume":"13","author":"Schilling","year":"1989","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"8","key":"10.1016\/j.ejpb.2025.114924_b0265","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1016\/j.clnu.2019.11.014","article-title":"In vitro compatibility studies of vancomycin with ready-to-use parenteral nutrition admixtures for safer clinical practice","volume":"39","author":"Stawny","year":"2020","journal-title":"Clin. Nutr."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0270","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/0148607192016003268","article-title":"Vancomycin stability in heparin and total parenteral nutrition solutions: novel approach to therapy of central venous catheter-related infections.","volume":"16","author":"Yao","year":"1992","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0275","doi-asserted-by":"crossref","first-page":"09","DOI":"10.3390\/antibiotics10050549","article-title":"Stability and compatibility aspects of drugs: the case of selected cephalosporins","volume":"10","author":"Tomczak","year":"2021","journal-title":"Antibiotics"},{"issue":"10","key":"10.1016\/j.ejpb.2025.114924_b0280","first-page":"2208","article-title":"Stability of cimetidine hydrochloride in a total nutrient admixture","volume":"42","author":"Baptista","year":"1985","journal-title":"Am. J. Hosp. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0285","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/014860719401800405","article-title":"Histamine receptor antagonists and lipid stability in total nutrient admixtures.","volume":"18","author":"Hatton","year":"1994","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0290","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/106002808902300515","article-title":"Stability of cimetidine HCl and copper sulfate in a TPN solutions","volume":"23","author":"Mitrano","year":"1989","journal-title":"DICP"},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0295","first-page":"311","article-title":"Stability and compatibility of histamine H2-receptor antagonists in parenteral nutrition mixtures","volume":"10","author":"Puzovic","year":"2007","journal-title":"Curr. Opin. Clin. Nutr. Metabolic Care"},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0300","first-page":"390","article-title":"Cimetidine hydrochloride compatibility. I: chemical aspects and room temperature stability in intravenous infusion fluids","volume":"37","author":"Rosenberg","year":"1980","journal-title":"Am. J. Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0305","first-page":"484","article-title":"Stability of cimetidine hydrochloride in parenteral nutrition solutions","volume":"39","author":"Tsallas","year":"1982","journal-title":"Am. J. Hosp. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114924_b0310","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0899-9007(97)00034-8","article-title":"Stability of ranitidine and thiamine in parenteral nutrition solutions","volume":"13","author":"Baumgartner","year":"1997","journal-title":"Nutrition"},{"issue":"12","key":"10.1016\/j.ejpb.2025.114924_b0315","first-page":"2683","article-title":"Stability of ranitidine hydrochloride and amino acids in parenteral nutrient solutions","volume":"42","author":"Bullock","year":"1985","journal-title":"Am. J. Hosp. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0320","first-page":"1100","article-title":"Stability of ranitidine hydrochloride in total nutrient admixtures","volume":"45","author":"Cano","year":"1988","journal-title":"Am. J. Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0325","first-page":"590","article-title":"Stability of ranitidine hydrochloride in total parenteral nutrient solution","volume":"42","author":"Walker","year":"1985","journal-title":"Am. J. Hosp. Pharm."},{"issue":"7","key":"10.1016\/j.ejpb.2025.114924_b0330","first-page":"1574","article-title":"In vitro evaluation of the stability of ranitidine hydrochloride in total parenteral nutrient mixtures","volume":"47","author":"Williams","year":"1990","journal-title":"Am. J. Hosp. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0335","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1130-6343(08)75949-X","article-title":"Stability of pantoprazole in parenteral nutrition units","volume":"32","author":"Valverde Molina","year":"2008","journal-title":"Farm. Hosp."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0340","first-page":"503","article-title":"Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions","volume":"51","author":"Johnson","year":"1994","journal-title":"Am. J. Hosp. Pharm."},{"issue":"7","key":"10.1016\/j.ejpb.2025.114924_b0345","first-page":"1538","article-title":"Visual compatibility of ganciclovir sodium and total parenteral nutrient solution during simulated Y-site injection","volume":"48","author":"Outman","year":"1991","journal-title":"Am. J. Hosp. Pharm."},{"key":"10.1016\/j.ejpb.2025.114924_b0350","doi-asserted-by":"crossref","unstructured":"Moshfeghi, M. and J.D. Ciuffo, Visual compatibility of fentanyl citrate with parenteral nutrient solutions. Am. J. Health-Syst. Pharm., 1998. 55(11): p. 1194, 1197.","DOI":"10.1093\/ajhp\/55.11.1194"},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0355","first-page":"1087","article-title":"Stability of morphine sulfate and meperidine hydrochloride in a parenteral nutrient formulation","volume":"42","author":"Macias","year":"1985","journal-title":"Am. J. Hosp. Pharm."},{"key":"10.1016\/j.ejpb.2025.114924_b0360","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ejps.2016.10.015","article-title":"Physicochemical stability and compatibility testing of levetiracetam in all-in-one parenteral nutrition admixtures in daily practice","volume":"96","author":"Aeberhard","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0365","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ajhp\/52.2.192","article-title":"Stability of propofol with parenteral nutrient solutions during simulated Y-site injection","volume":"52","author":"Bhatt-Mehta","year":"1995","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0370","first-page":"285","article-title":"Stability of midazolam hydrochloride in parenteral nutrient solutions","volume":"50","author":"Bhatt-Mehta","year":"1993","journal-title":"Am. J. Hosp. Pharm."},{"issue":"11","key":"10.1016\/j.ejpb.2025.114924_b0375","first-page":"2326","article-title":"Stability of famotidine 20 and 50 mg\/L in total nutrient admixtures","volume":"46","author":"Bullock","year":"1989","journal-title":"Am. J. Hosp. Pharm."},{"issue":"11","key":"10.1016\/j.ejpb.2025.114924_b0380","first-page":"2321","article-title":"Stability of famotidine 20 and 40 mg\/L and amino acids in total parenteral nutrient solutions","volume":"46","author":"Bullock","year":"1989","journal-title":"Am. J. Hosp. Pharm."},{"issue":"10 Suppl","key":"10.1016\/j.ejpb.2025.114924_b0385","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1177\/1060028089023S1008","article-title":"Stability of famotidine in minibags refrigerated and\/or frozen in total parenteral nutrition solutions","volume":"23","author":"Bullock","year":"1989","journal-title":"DICP"},{"issue":"6","key":"10.1016\/j.ejpb.2025.114924_b0390","first-page":"487","article-title":"Aminophylline stability in total parenteral nutrition admixtures","volume":"52","author":"Ciszewska-Jedrasik","year":"1995","journal-title":"Acta Pol. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114924_b0395","first-page":"1459","article-title":"Stability of fluconazole and amino acids in parenteral nutrient solutions","volume":"49","author":"Couch","year":"1992","journal-title":"Am. J. Hosp. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0400","first-page":"307","article-title":"Compatibility of hydromorphone hydrochloride in large-volume parenterals","volume":"39","author":"Cutie","year":"1982","journal-title":"Am. J. Hosp. Pharm."},{"key":"10.1016\/j.ejpb.2025.114924_b0405","unstructured":"de Juana, P., et al., [The stability of antibiotics administered in \u201cand\u201d with a parenteral nutrition mixture enriched with branched-chain amino acids. II. The cephalosporins]. Nutricion Hospitalaria, 1993. 8(8): p. 479-88."},{"issue":"11","key":"10.1016\/j.ejpb.2025.114924_b0410","first-page":"2333","article-title":"Long-term stability of famotidine 20 mg\/L in a total parenteral nutrient solution","volume":"46","author":"DiStefano","year":"1989","journal-title":"Am. J. Hosp. Pharm."},{"issue":"12","key":"10.1016\/j.ejpb.2025.114924_b0415","first-page":"1955","article-title":"Daily digoxin administration in parenteral nutrition solution","volume":"38","author":"Fagerman","year":"1981","journal-title":"Am. J. Hosp. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0420","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/jpen.1024","article-title":"Insulin instability in parenteral nutrition admixtures.","volume":"42","author":"Forchielli","year":"2018","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114924_b0425","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/pharmaceutics12010027","article-title":"The interactions between ciprofloxacin and parenteral nutrition admixtures","volume":"12","author":"Gostynska","year":"2019","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0430","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0148607182006002163","article-title":"Compatibility of 5-fluorouracil and total parenteral nutrition solutions.","volume":"6","author":"Hardin","year":"1982","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"7","key":"10.1016\/j.ejpb.2025.114924_b0435","first-page":"1507","article-title":"Stability of nizatidine in total nutrient admixtures","volume":"48","author":"Hatton","year":"1991","journal-title":"Am. J. Hosp. Pharm."},{"issue":"12","key":"10.1016\/j.ejpb.2025.114924_b0440","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/ajhp\/54.12.1449a","article-title":"Precipitation of amphotericin B from i.v. fat emulsion","volume":"54","author":"Heide","year":"1997","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"12","key":"10.1016\/j.ejpb.2025.114924_b0445","first-page":"2718","article-title":"Compatibility and availability of sodium bicarbonate in total parenteral nutrient solutions","volume":"42","author":"Henann","year":"1985","journal-title":"Am. J. Hosp. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0450","first-page":"687","article-title":"Compatibility of cyclosporine with fat emulsion","volume":"50","author":"Jacobson","year":"1993","journal-title":"Am. J. Hosp. Pharm."},{"issue":"14","key":"10.1016\/j.ejpb.2025.114924_b0455","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/ajhp\/52.14.1557","article-title":"Stability of ondansetron hydrochloride in a total parenteral nutrient admixture","volume":"52","author":"Kirkham","year":"1995","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0460","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jpen.1419","article-title":"Physicochemical compatibility of amiodarone with parenteral nutrition.","volume":"43","author":"Mediavilla","year":"2019","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"11","key":"10.1016\/j.ejpb.2025.114924_b0465","first-page":"2329","article-title":"Stability of famotidine 20 and 40 mg\/L in total nutrient admixtures","volume":"46","author":"Montoro","year":"1989","journal-title":"Am. J. Hosp. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114924_b0470","first-page":"31","article-title":"Continuous intravenous administration of 1-(2-tetrahydrofuryl)-5-fluorouracil [FT] by intravenous hyperalimentation (IVH)\u2013stability of FT in IVH solution and tumor levels of 5-fluorouracil (5-FU)","volume":"13","author":"Moriya","year":"1983","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0475","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/ajhp\/54.2.181","article-title":"Compatibility of commonly used bone marrow transplant drugs during Y-site delivery","volume":"54","author":"Najari","year":"1997","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0480","first-page":"428","article-title":"Stability of aminophylline injection in three parenteral nutrient solutions","volume":"40","author":"Niemiec","year":"1983","journal-title":"Am. J. Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0485","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ajhp\/62.3.289","article-title":"Stability of roxatidine acetate in parenteral nutrient solutions containing different amino acid formulations","volume":"62","author":"Oh","year":"2005","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0490","first-page":"715","article-title":"Visual compatibility of ciprofloxacin with selected components of total parenteral nutrient solutions during simulated Y-site injection","volume":"50","author":"Percy","year":"1993","journal-title":"Am. J. Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0495","first-page":"592","article-title":"Stability of cytarabine in a parenteral nutrient solution","volume":"42","author":"Quock","year":"1985","journal-title":"Am. J. Hosp. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114924_b0500","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/jac\/37.6.1165","article-title":"Amphotericin B intralipid formulation: stability and particle size","volume":"37","author":"Ranchere","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.ejpb.2025.114924_b0505","first-page":"2172","article-title":"Activity of octreotide acetate in a total nutrient admixture","volume":"48","author":"Ritchie","year":"1991","journal-title":"Am. J. Hosp. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114924_b0510","first-page":"98","article-title":"Somatostatin stability in parenteral nutrition units","volume":"6","author":"Ronchera-Oms","year":"1991","journal-title":"Nutr. Hosp."},{"key":"10.1016\/j.ejpb.2025.114924_b0515","doi-asserted-by":"crossref","unstructured":"Saavedra-Mitjans, M., et al., Physicochemical compatibility of dexmedetomidine with total parenteral nutrition...European Society for Clinical Nutrition and Metabolism (ESPEN) 40th Congress, September 1-4, 2018, Madrid, Spain. Clinical Nutrition, 2018. 37: p. S312-S313.","DOI":"10.1016\/j.clnu.2018.06.2089"},{"issue":"5","key":"10.1016\/j.ejpb.2025.114924_b0520","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/10837450.2020.1720237","article-title":"Development, characterization and stability evaluation of ciprofloxacin-loaded parenteral nutrition nanoemulsions","volume":"25","author":"Said Suliman","year":"2020","journal-title":"Pharm. Develop. Tech."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0525","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/106002809002400302","article-title":"Stability of famotidine in a 3-in-1 total nutrient admixture","volume":"24","author":"Shea","year":"1990","journal-title":"DICP"},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0530","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/pharmaceutics12030292","article-title":"Safe practice of Y-site drug administration: the case of Colistin and parenteral nutrition","volume":"12","author":"Stawny","year":"2020","journal-title":"Pharmaceutics"},{"issue":"d7","key":"10.1016\/j.ejpb.2025.114924_b0535","first-page":"29","article-title":"Physicochemical compatibility and stability of linezolid with parenteral nutrition","volume":"24","author":"Tomczak","year":"2019","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.ejpb.2025.114924_b0540","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/pharmaceutics12111092","article-title":"Co-administration of drugs and parenteral nutrition: in vitro compatibility studies of loop diuretics for safer clinical practice","volume":"12","author":"Tomczak","year":"2020","journal-title":"Pharmaceutics"},{"issue":"13","key":"10.1016\/j.ejpb.2025.114924_b0545","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/ajhp\/52.13.1463","article-title":"Amphotericin B does not mix with fat emulsion","volume":"52","author":"Trissel","year":"1995","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0550","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1128\/AAC.42.4.762","article-title":"Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity","volume":"42","author":"Walker","year":"1998","journal-title":"Antimicrobial Agents Chemother."},{"issue":"21","key":"10.1016\/j.ejpb.2025.114924_b0555","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015747","article-title":"Evaluation of Y-site compatibility of home total parenteral nutrition and intravenous loop diuretics","volume":"98","author":"Watrobska-Swietlikowska","year":"2019","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.ejpb.2025.114924_b0560","first-page":"353","article-title":"Availability of insulin from parenteral nutrient solutions","volume":"34","author":"Weber","year":"1977","journal-title":"Am. J. Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114924_b0565","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/0148607190014003306","article-title":"Stability of imipenem and cilastatin sodium in total parenteral nutrient solution.","volume":"14","author":"Zaccardelli","year":"1990","journal-title":"Jpen: J. Parenteral Enteral Nutr."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114924_b0570","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2146\/ajhp110715","article-title":"Physical compatibility of various drugs with neonatal \u03b3-site administration","volume":"70","author":"Fox","year":"2013","journal-title":"Am. J. Health Syst. Pharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125003017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125003017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:38:34Z","timestamp":1768433914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125003017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":114,"alternative-id":["S0939641125003017"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114924","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compatibility of parenteral nutrition solutions with intravenous medication in infants and children: A literature review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114924"}}